Cell Free System Market: Cell free Expression Kits and Service Providers - Distribution by Type of Cell Free System (Crude Cell Lysate-Based Systems and Reconstituted Systems), Type of Host Organism (Microbial Cell Free Expression System, Mammalian Cell Free Expression System, Plant-based Cell Free Expression System and Other Cell Free Expression Systems), Type of Expression Method (Coupled Transcription and Translation Method and Translation Method), End-User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes and Other End-Users) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035

June 2023 | 192 pages | ID: CD07F01A2FBBEN
Roots Analysis

Abstracts

The global cell free expression market is expected to reach USD 275 million by 2023 anticipated to grow at a CAGR of 7.5% during the forecast period 2023-2035

In recent years, the biopharmaceutical sector has seen significant growth within the pharmaceutical industry. Notably, a substantial portion of newly approved drugs by the FDA's Center for Drug Evaluation and Research are biologics, emphasizing their increasing importance. This has led to a rise in biologics and biosimilars development, heavily relying on living biological systems. Consequently, there's been a heightened demand for various cell lines, with approximately 84% of therapeutic proteins produced in the last five years using diverse mammalian and microbial cells. However, a recent study discovered a concerning issue: around 30,000 research articles across various journals featured data derived from experiments using misidentified or contaminated cell lines. This poses a significant challenge in medical research, particularly as the field increasingly depends on cell-based assays and experiments. Hence, ensuring accurate characterization of cell lines has become imperative to maintain authenticity and precision in modern medical studies.

In the cost-intensive realm of pharmacological research and development, professionals are consistently seeking ways to improve operational efficiencies and reduce costs. Consequently, outsourcing has become a favored business model. Many service providers now claim expertise in developing and characterizing cell lines, tailored to the specific needs of drug developers. The technical landscape in this field is experiencing considerable innovation, particularly in automating various stages of cell line development. Additionally, advanced genome editing technologies like CRISPR/Cas-9 are extensively utilized to enhance the quality of recombinant cell lines. Unlike drug developers, service providers typically specialize in particular service portfolios. They prioritize staying abreast of the latest equipment and infrastructure advancements to ensure service quality. Furthermore, many service providers have recently forged strategic partnerships or undergone acquisitions with other entities to bolster their service offerings and expand their portfolios. Considering the prevalent trend of outsourcing and the ongoing efforts of service providers to enhance their services, it is anticipated that the contract services market for cell line development and characterization will steadily evolve until 2030.

Report Coverage

• The study delves into the cell-free expression market, examining various aspects such as types of expression systems, host organisms, expression methods, end-users, and geographical regions. It analyzes factors like market drivers, restraints, opportunities, and challenges influencing market growth.
• Furthermore, it evaluates the potential advantages and barriers within the market, providing insights into the competitive landscape for leading market players. The report forecasts revenue across major regions and offers an executive summary detailing key findings, market overview, challenges, advantages, healthcare and industry applications, and future prospects.
• A detailed assessment includes parameters such as establishment year, company size, headquarters location, offered services (synthesis, template construction, scaled-up production), associated services (purification, quality control), host organisms, products synthesized, scale of operation, and industries served.
• The evaluation considers cell-free system types, host organisms, expression methods, synthesized products, templates used, reaction formats, yields, reaction details, volume, temperature, reactions per kit, and pricing. It covers details about developers, establishment year, company size, and major players.
• Additionally, service providers are evaluated based on supplier power and service strength, taking into account experience, host organisms, services offered, products synthesized, industries served, and scale of operation. Expression kits are analyzed concerning developer experience and competitiveness across various parameters.
• The report provides detailed profiles of significant service providers and expression kit developers, focusing on their service/portfolio details, recent developments, and future outlook. It also covers partnerships since 2018, encompassing product development, research agreements, acquisitions, alliances, joint ventures, technology licensing, and commercialization agreements.
• Furthermore, it examines funding types (seed, venture capital, IPOs, grants), amounts, stages, leading players, investors, and geographical distribution since 2018. An in-depth analysis of patents related to cell-free systems since 2015 includes publication years, types, jurisdictions, applicant types, focus areas, leading players, individual assignees, benchmarking, valuation, and citation analysis.

Key Market Companies

• BioLinker
• biotechrabbit
• CellFreeSciences
• Creative Biolabs
• CUSABIO
• Daicel Arbor Biosciences
• LenioBio
• Promega
• Thermo Fisher Scientific
• Touchlight

Contents

1. PREFACE

1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Introduction to Cell Free Systems
3.3. Overview of Cell Free Biomanufacturing
  3.3.1. Advantages
  3.3.2. Challenges
3.4. Applications of Cell Free Biomanufacturing
  3.4.1. Applications in Healthcare Domain
  3.4.2. Applications in Other Domains
3.5. Future Perspectives

4. MARKET LANDSCAPE: CELL FREE EXPRESSION SERVICE PROVIDERS

4.1. Chapter Overview
4.2. Cell Free Expression Service Providers: Overall Market Landscape
  4.2.1. Analysis by Year of Establishment
  4.2.2. Analysis by Company Size
  4.2.3. Analysis by Location of Headquarters
  4.2.4. Analysis by Type of Cell Free Expression Service(s) Offered
  4.2.5. Analysis by Type of Associated Service(s) Offered
  4.2.6. Analysis by Type of Host Organism
  4.2.7. Analysis by Type of Product(s) Synthesized
  4.2.8. Analysis by Scale of Operation
  4.2.9. Analysis by Type of Industry Served

5. MARKET LANDSCAPE: CELL FREE EXPRESSION KITS

5.1. Chapter Overview
5.2. Cell Free Expression Kits: Overall Market Landscape
  5.2.1. Analysis by Type of Cell Free System
  5.2.2. Analysis by Type of Host Organism
  5.2.3. Analysis by Type of Expression Method
  5.2.4. Analysis by Type of Product(s) Synthesized
  5.2.5. Analysis by Type of Template(s) Used
  5.2.6. Analysis by Type of Compatible Promoter(s)
  5.2.7. Analysis by Type of Reaction Format
  5.2.8. Analysis by Yield of Positive Control
  5.2.9. Analysis by Reaction Volume
  5.2.10. Analysis by Reaction Temperature
  5.2.11. Analysis by Incubation Time
  5.2.12. Analysis by Number of Reactions per Kit
  5.2.13. Analysis by Kit Price
5.3. Cell Free Expression Kit Providers Landscape
  5.3.1. Analysis by Year of Establishment
  5.3.2. Analysis by Company Size
  5.3.3. Analysis by Location of Headquarters
  5.3.4. Most Active Players: Analysis by Number of Cell free Expression Kits Developed

6. CELL FREE EXPRESSION SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS

6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Company Competitiveness Analysis: Cell Free Expression Service Providers
  6.4.1. Company Competitiveness Analysis: Small Service Providers
  6.4.2. Company Competitiveness Analysis: Mid-sized Service Providers
  6.4.3. Company Competitiveness Analysis: Large and Very Service Providers

7. CELL FREE EXPRESSION KITS: PRODUCT COMPETITIVENESS ANALYSIS

7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. Product Competitiveness Analysis: Cell Free Expression Kits
  7.4.1. Product Competitiveness Analysis: Cell Free Expression Kits Developed by Players based in North America
  7.4.2. Product Competitiveness Analysis: Cell Free Expression Kits Developed by Players based in Europe
  7.4.3. Product Competitiveness Analysis: Cell Free Expression Kits Developed by Players based in Asia-Pacific and Rest of the World

8. COMPANY PROFILES: CELL FREE EXPRESSION SERVICE PROVIDERS

8.1. Chapter Overview
8.2. BioLinker
  8.2.1. Company Overview
  8.2.2. Cell Free Expression Service Portfolio
  8.2.3. Recent Developments and Future Outlook
8.3. CUSABIO
  8.3.1. Company Overview
  8.3.2. Cell Free Expression Service Portfolio
  8.3.3. Recent Developments and Future Outlook
8.4. LenioBio
  8.4.1. Company Overview
  8.4.2. Cell Free Expression Service Portfolio
  8.4.3. Recent Developments and Future Outlook
8.5. Touchlight
  8.5.1. Company Overview
  8.5.2. Cell Free Expression Service Portfolio
  8.5.3. Recent Developments and Future Outlook

9. COMPANY PROFILES: CELL FREE EXPRESSION KIT PROVIDERS

9.1. Chapter Overview
9.2. biotechrabbit
  9.2.1. Company Overview
  9.2.2. Cell Free Expression Kit Portfolio
  9.2.3 Recent Developments and Future Outlook
9.3. CellFree Sciences
  9.3.1. Company Overview
  9.3.2. Cell Free Expression Kit Portfolio
  9.3.3 Recent Developments and Future Outlook
9.4. Creative Biolabs
  9.4.1. Company Overview
  9.4.2. Cell Free Expression Kit Portfolio
  9.4.3 Recent Developments and Future Outlook
9.5. Diacel Arbor Biosciences
  9.5.1. Company Overview
  9.5.2. Cell Free Expression Kit Portfolio
  9.5.3 Recent Developments and Future Outlook
9.6. Promega
  9.6.1. Company Overview
  9.6.2. Cell Free Expression Kit Portfolio
  9.6.3 Recent Developments and Future Outlook
9.7. Thermo Fisher Scientific
  9.7.1. Company Overview
  9.7.2. Cell Free Expression Kit Portfolio
  9.7.3. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS

10.1. Chapter Overview
10.2. Partnership Models
10.3. Cell free System: Partnerships and Collaborations
  10.3.1 Analysis by Year of Partnership
  10.3.2. Analysis by Type of Partnership
  10.3.3. Analysis by Year and Type of Partnership
  10.3.4. Analysis by Focus Area
  10.3.5. Analysis by Type of Partner
  10.3.6. Most Active Players: Analysis by Number of Partnerships
  10.3.7. Local and International Agreements
  10.3.8. Intercontinental and Intracontinental Agreements

11. FUNDING AND INVESTMENT ANALYSIS

11.1. Chapter Overview
11.2. Types of Funding
11.3. Cell free System: Funding and Investment Analysis
  11.3.1. Analysis of Instances by Year of Investment
  11.3.2. Analysis of Amount Invested by Year of Investment
  11.3.3. Analysis of Instances by Type of Funding
  11.3.4. Analysis of Amount Invested by Type of Funding
  11.3.5. Analysis by Instances of Type of Investor
  11.3.6. Most Active Players: Analysis by Number of Instances
  11.3.7. Most Active Players: Analysis by Amount Invested
  11.3.8. Analysis of Amount Invested by Geography
    11.3.8.1. Analysis by Region
    11.3.8.2. Analysis by Country

12. PATENT ANALYSIS

12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Cell free System: Patent Analysis
  12.3.1. Analysis by Patent Publication Year
  12.3.2. Analysis by Patent Application Year
  12.3.3. Analysis by Annual Number of Granted Patents and Patent Applications
  12.3.4. Analysis by Patent Jurisdiction
  12.3.5. Analysis by CPC Symbols
  12.3.6. Analysis by Type of Applicant
  12.3.7. Leading Industry Players: Analysis by Number of Patents
  12.3.8. Leading Non-Industry Players: Analysis by Number of Patents
  12.3.9. Leading Individual Assignees: Analysis by Number of Patents
12.4. Cell free System: Patent Benchmarking Analysis
  12.4.1. Analysis by Patent Characteristics
12.5. Cell free System: Patent Valuation
12.6. Leading Patents: Analysis by Number of Citations

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS

13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global Cell Free Expression Market, 2023-2035
  13.3.1. Cell Free Expression Market: Distribution by Type of Cell Free System, 2023 and 2035
    13.3.1.1. Cell Free Expression Market for Crude Cell Lysate-based Systems, 2023-2035
    13.3.1.2. Cell Free Expression Market for Reconstituted Systems, 2023-2035
  13.3.2. Cell Free Expression Market: Distribution by Type of Host Organism, 2023 and 2035
    13.3.2.1. Cell Free Expression Market for Microbial Cell Free Expression Systems, 2023-2035
    13.3.2.2. Cell Free Expression Market for Mammalian Cell Free Expression Systems, 2023-2035
    13.3.2.3. Cell Free Expression Market for Plant-based Cell Free Expression Systems, 2023-2035
    13.3.2.4. Cell Free Expression Market for Other Cell Free Expression Systems, 2023-2035
  13.3.3. Cell Free Expression Market: Distribution by Type of Expression Method, 2023 and 2035
    13.3.3.1. Cell Free Expression Market for Coupled Transcription and Translation Method, 2023-2035
    13.3.3.2. Cell Free Expression Market for Translation Method, 2023-2035
  13.3.4. Cell Free Expression Market: Distribution by End-User, 2023 and 2035
    13.3.4.1. Cell Free Expression Market for Pharmaceutical and Biotechnology Companies, 2023-2035
    13.3.4.2. Cell Free Expression Market for Academic and Research Institutes, 2023-2035
    13.3.4.3. Cell Free Expression Market for Other End-Users, 2023-2035
  13.3.5. Cell Free Expression Market: Distribution by Key Geographical Regions, 2023 and 2035
    13.3.5.1. Cell Free Expression Market in North America, 2023-2035
    13.3.5.2. Cell Free Expression Market in Europe, 2023-2035
    13.3.5.3. Cell Free Expression Market in Asia-Pacific, 2023-2035
    13.3.5.4. Cell Free Expression Market in Rest of the World, 2023-2035

14. EXECUTIVE INSIGHTS

14.1. Chapter Overview
14.2. Gene Frontier
  14.2.1. Company Snapshot
  14.2.2. Interview Transcript: Takashi Ebihara, Chief Operational Officer
14.3. LenioBio
  14.3.1. Company Snapshot
  14.3.2. Interview Transcript: Remberto Martis, Founder and Chief Executive Officer

15. CONCLUDING REMARKS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS